A Immunotherapy research project developed by FFUL and the Tel Aviv University (TAU) was selected, in June 2021, to be part of the Nanotechnology Characterization Laboratory (NCL) international program established by the National Cancer Institute (NCI), in the USA.

The study, coordinated by Helena Florindo (FFUL) and Ronit Satchi-Fainaro (TAU), focuses on an immunotherapy based on nanoparticles that aims to activate immune cells with the aim of improving therapeutic efficacy and enhancing the elimination of cancer. This integration into the NCL program provides detailed characterization of the physicochemical properties of the formulation, allows the assessment (by an independent laboratory) of its safety and efficacy and also validates the feasibility for clinical use.

The results of the characterization process will be crucial to accelerate the conversion of immunotherapy into new therapies for cancer patients.